SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC).

Authors

Antoinette J. Wozniak

Karmanos Cancer Institute, Wayne State University, Detroit, MI

Antoinette J. Wozniak , James Moon , Charles R. Thomas Jr., Karen Kelly , Philip C. Mack , Laurie E. Gaspar , David Raben , Kishan J. Pandya , David R. Gandara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

First Author: John M. Varlotto

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation.

First Author: Ligang Xing

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Concurrent chemoradiation (CChRT) with bi-weekly docetaxel and cisplatin and thoracic radiotherapy for stage III non-small cell lung cancer (NSCLC): A phase II study from the Galician Lung Cancer Group.

First Author: Joaquin Casal Rubio

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Induction chemotherapy (CT) with docetaxel, cisplatin, and fluorouracil (TPF) followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer (NPC): Results after 06 years.

First Author: Esma Kerboua